Exosome launches MedOncAlyzer pan-cancer panel

by • August 11, 2017 • Feature Slider, Feature-Home, Featured-Slides-HomeComments Off on Exosome launches MedOncAlyzer pan-cancer panel266

Exosome Diagnostics’ MedOncAlyzer 170 is the first liquid biopsy pan-cancer panel that simultaneously interrogates exosomal RNA (exoRNA) and circulating tumor DNA (ctDNA) in a single assay, according to the liquid biopsy solutions company.

The MedOncAlyzer 170 is a targeted panel for tumor profiling that identifies clinically actionable and functionally important mutations across multiple cancer types starting from a small volume (≥ 0.5ml) of patient blood or plasma.

“The MedOncAlyzer is the only cancer panel on the market that interrogates information on both RNA and DNA, giving it a higher sensitivity compared to ctDNA assays when profiling early stage and late stage cancers in plasma,” said Johan Skog, chief science officer of Exosome Diagnostics. “ctDNA-only solutions are seeing their most accurate measurements in late stage cancers.”

The primary drivers of ctDNA release into the bloodstream are apoptosis and necrosis of tumor cells. However, Skog said existing solutions that rely on ctDNA alone are building a profile of the tumor that is biased towards consequences of cell death.

“Exosomes, in contrast, are actively released by living cells including viable tumor cells,” Skog explained “The MedOncAlyzer, with its unique ability to co-isolate RNA and DNA, is balanced to produce accurate, highly sensitive identification of rare variants through all stages of disease progression and treatment, including RNA variants that cannot be seen on ctDNA.”

The MedOncAlyzer 170 panel uses the proprietary Exosome Diagnostics technologies including nucleic acid co-isolation, target capture, and bioinformatics to yield unprecedented sensitivity and scope:

  • 170 clinically actionable and functionally relevant gene targets
  • Capture and sequencing of complete coding regions for all targets
  • 99.9 per cent sensitivity for mutations at allele fractions of ≥ 0.1 per cent
  • Ability to detect RNA-specific events such as gene fusions and splice variants
  • Complete panel coverage from ≥ 0.5ml of starting material (plasma)
  • Double the nucleic acid extracted per ml of sample volume versus ctDNA alone
  • 82,000 COSMIC variants interrogated

“The MedOncAlyzer assay consistently produces on average three-fold more total nucleic acid concentration per ml of starting plasma over ctDNA-only protocols,” said John Healy, vice-presing of informatics at Exosome.  “The overall sensitivity of the MedOncAlyzer assay is, by definition, greater than any products that look at ctDNA alone. “

“Our critical advantage in this co-isolation stage means that the MedOncAlyzer is making the most efficient use of sequencing coverage,” he said. “This has allowed us to vastly increase the breadth of our panel without sacrificing depth of sequencing coverage.”

“We are already experiencing tremendous demand for the MedOncAlyzer panel from our pharma partners and academic collaborators,” said John Boyce, CEO of Exosome. “The value of our ability to perform such comprehensive tumor profiling from as little as 0.5ml of starting material is clear.”

For more information about the MedOncAlyzer 170, email bd@exosomedx.com or visit www.exosomedx.com to learn more.


Comments are closed.